



Where the Magic of Collaboration
Meets the Power of Science
About the Event
Packard Center Meeting
Four Seasons: Baltimore, Maryland
March 1, 2026
5:00 to 7:00 pm
Join us for IgNight, an event dedicated to accelerating the defeat of ALS through bold new partnerships. Visionary leaders from major technology companies, biotech innovators, and influential industry voices will take the stage to reveal how strategic alignments with industry, nonprofit organizations, and philanthropic powerhouses are already reshaping ALS research and will dramatically accelerate cures in the years ahead. These speakers will share actionable insights, funding pathways, and collaboration opportunities specifically designed to empower the scientists and researchers in the room. Between inspiring talks, enjoy high-energy, ALS-relevant performances and interactive experiences that celebrate resilience, innovation, and the unbreakable human spirit driving this fight. IgNight isn’t just an event, it’s the spark that turns connections into breakthroughs.

About Answer ALS
Answer ALS began in 2014, when former NFL player, Steve Gleason, who is living with ALS, hosted a summit and asked researchers, clinicians and ALS patients and caregivers to develop a business plan to end the disease. Ultimately, that plan became Answer ALS.
The Answer ALS program is creating the largest and most comprehensive foundation of ALS data ever amassed from an enormous sampling of ALS patient participants and freely sharing to researchers around the world. The data and biological samples are being mined to uncover ALS causes, subtypes, pathways gone awry and drug targets. Over 500 independent ALS research projects have resulted from the Answer ALS resource to date.
These efforts could also potentially provide deeper understanding of Alzheimers, Parkinsons and other neurodegenerative diseases.
ALS in the US
30K+
2
6
5K+
0
People with ALS
Treatments
Drugs in Phase 3
Deaths annually
Cure
Past Speakers : Presenters
Stay Tuned for 2026!
Sponsors



.png)

.png)










